Cell Therapy

News

Preparing for an influx of cell and gene therapy approvals

CapstanTx secures $165 million to deliver precise in vivo ce...

Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo

News

ESMO: TIL therapy improves on Yervoy in melanoma trial

A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has been shown to be more effective at improving progression-free survival than Bristol-Myers Squibb's immuno

Partner Content

iPSC Pharma Phorum banner (1422 × 800 px)

Partner Content

2nd iPSC-Derived Cell Therapies Summit

The Industry's Largest Event Showcasing iPSC Therapies

News

Vertex buys diabetes cell therapy rival ViaCyte for $320m

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880.

Oncology

Partner Content

CAR:T - Has biology outpaced the ability to deliver?

CAR-T, the latest development in research is catapulting cell therapy to the headlines.

News

Astellas teams up with UK biotech Mogrify on hearing loss pr...

Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused by factors such as chronic ex

CapstanTx secures $165 million to deliver precise in vivo ce...

ESMO: TIL therapy improves on Yervoy in melanoma trial

2nd iPSC-Derived Cell Therapies Summit

Vertex buys diabetes cell therapy rival ViaCyte for $320m

CAR:T - Has biology outpaced the ability to deliver?

Astellas teams up with UK biotech Mogrify on hearing loss pr...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Cell Therapy

Editor's Picks